Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Extension Study for Participants from Previous Pembrolizumab Studies
NCT03486873Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2018
- Primary completion
- Aug 2043
- Countries
- 51
01
Overview
A Phase 3 trial of pembrolizumab in solid tumor, hematologic malignancy, sponsored by Merck & Co.. Started Aug 2018; status: recruiting.
02
Drugs
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT03486873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486873.